Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers

Journal of Controlled Release

Volumn 189, Issue , 2014, Pages 72-79

  Nagano, Kazuya ^a   Maeda, Yuka ^a,b   Kanasaki, So Ichiro ^a,b   Watanabe, Takanobu ^a,b   Yamashita, Takuya ^a,b   Inoue, Masaki ^a   Higashisaka, Kazuma ^a,b   Yoshioka, Yasuo ^a,b   Abe, Yasuhiro ^a   Mukai, Yohei ^a   Kamada, Haruhiko ^a,b   Tsutsumi, Yasuo ^b   Tsunoda, Shin Ichi ^a,b  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Antibody drug; Cell proliferation; Ephrin receptor A10; Triple negative breast cancer

Indexed keywords

CELL PROLIFERATION; HISTOLOGY; MONOCLONAL ANTIBODIES; TISSUE;

ANTIBODY DRUGS; BREAST CANCER; BREAST TISSUES; EPHRIN RECEPTOR A10; IMMUNOHISTOCHEMICAL STAINING; NORMAL TISSUE; TISSUE SECTIONS; TRIPLE-NEGATIVE BREAST CANCERS;

DISEASES;

BEVACIZUMAB; EPHRIN A3; EPHRIN A4; EPHRIN A5; EPHRIN RECEPTOR; EPHRIN RECEPTOR A10; LIGAND; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY EPHA10; PERTUZUMAB; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPHA10 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CELL PROLIFERATION; COLON; CONTROLLED STUDY; DIMERIZATION; DRUG TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TESTIS; TISSUE MICROARRAY; TISSUE SECTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; HUMANS; MALE; MICE, INBRED BALB C; MOLECULAR TARGETED THERAPY; RECEPTOR, ERBB-2; RECEPTORS, EPH FAMILY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TESTIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903952284     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.06.010     Document Type: Article

References (43)

1. S.X. Lin, J. Chen, M. Mazumdar, D. Poirier, C. Wang, A. Azzi, and M. Zhou Molecular therapy of breast cancer: progress and future directions Nat. Rev. Endocrinol. 6 2010 485 493
2. A. Ocana, J.J. Cruz, and A. Pandiella Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance Am. J. Clin. Oncol. 29 2006 90 95
3. L. Carey, E. Winer, G. Viale, D. Cameron, and L. Gianni Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7 2010 683 692
4. S.K. Pal, B.H. Childs, and M. Pegram Triple negative breast cancer: unmet medical needs Breast Cancer Res. Treat. 125 2011 627 636
5. F. Podo, L.M. Buydens, H. Degani, R. Hilhorst, E. Klipp, I.S. Gribbestad, S. Van Huffel, H.W. van Laarhoven, J. Luts, D. Monleon, G.J. Postma, N. Schneiderhan-Marra, F. Santoro, H. Wouters, H.G. Russnes, T. Sorlie, E. Tagliabue, and A.L. Borresen-Dale Triple-negative breast cancer: present challenges and new perspectives Mol. Oncol. 4 2010 209 229
6. E.B. Pasquale Eph receptor signalling casts a wide net on cell behaviour Nat. Rev. Mol. Cell Biol. 6 2005 462 475
7. E.B. Pasquale Eph receptors and ephrins in cancer: bidirectional signalling and beyond Nat. Rev. Cancer 10 2010 165 180
8. J.G. Albeck, and J.S. Brugge Uncovering a tumor suppressor for triple-negative breast cancers Cell 144 2011 638 640
9. T. Sun, N. Aceto, K.L. Meerbrey, J.D. Kessler, C. Zhou, I. Migliaccio, D.X. Nguyen, N.N. Pavlova, M. Botero, J. Huang, R.J. Bernardi, E. Schmitt, G. Hu, M.Z. Li, N. Dephoure, S.P. Gygi, M. Rao, C.J. Creighton, S.G. Hilsenbeck, C.A. Shaw, D. Muzny, R.A. Gibbs, D.A. Wheeler, C.K. Osborne, R. Schiff, M. Bentires-Alj, S.J. Elledge, and T.F. Westbrook Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase Cell 144 2011 703 718
10. D.M. Brantley-Sieders, G. Zhuang, D. Hicks, W.B. Fang, Y. Hwang, J.M. Cates, K. Coffman, D. Jackson, E. Bruckheimer, R.S. Muraoka-Cook, and J. Chen The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling J. Clin. Invest. 118 2008 64 78
11. N. Munarini, R. Jager, S. Abderhalden, G. Zuercher, V. Rohrbach, S. Loercher, B. Pfanner-Meyer, A.C. Andres, and A. Ziemiecki Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase J. Cell Sci. 115 2002 25 37
12. D.P. Zelinski, N.D. Zantek, J.C. Stewart, A.R. Irizarry, and M.S. Kinch EphA2 overexpression causes tumorigenesis of mammary epithelial cells Cancer Res. 61 2001 2301 2306
13. S.R. Kumar, J. Singh, G. Xia, V. Krasnoperov, L. Hassanieh, E.J. Ley, J. Scehnet, N.G. Kumar, D. Hawes, M.F. Press, F.A. Weaver, and P.S. Gill Receptor tyrosine kinase EphB4 is a survival factor in breast cancer Am. J. Pathol. 169 2006 279 293
14. K.A. Mohammed, X. Wang, E.P. Goldberg, V.B. Antony, and N. Nasreen Silencing receptor EphA2 induces apoptosis and attenuates tumor growth in malignant mesothelioma Am. J. Cancer Res. 1 2011 419 431
15. N.K. Noren, M. Lu, A.L. Freeman, M. Koolpe, and E.B. Pasquale Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth Proc. Natl. Acad. Sci. U. S. A. 101 2004 5583 5588
16. S. Sawamiphak, S. Seidel, C.L. Essmann, G.A. Wilkinson, M.E. Pitulescu, T. Acker, and A. Acker-Palmer Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis Nature 465 2010 487 491
17. Y. Wang, M. Nakayama, M.E. Pitulescu, T.S. Schmidt, M.L. Bochenek, A. Sakakibara, S. Adams, A. Davy, U. Deutsch, U. Luthi, A. Barberis, L.E. Benjamin, T. Makinen, C.D. Nobes, and R.H. Adams Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis Nature 465 2010 483 486
18. D.M. Brantley-Sieders, W.B. Fang, D.J. Hicks, G. Zhuang, Y. Shyr, and J. Chen Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression FASEB J. 19 2005 1884 1886
19. M.S. Duxbury, H. Ito, M.J. Zinner, S.W. Ashley, and E.E. Whang EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma Oncogene 23 2004 1448 1456
20. X.D. Ji, G. Li, Y.X. Feng, J.S. Zhao, J.J. Li, Z.J. Sun, S. Shi, Y.Z. Deng, J.F. Xu, Y.Q. Zhu, H.P. Koeffler, X.J. Tong, and D. Xie EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration Cancer Res. 71 2011 1156 1166
21. D. Jackson, J. Gooya, S. Mao, K. Kinneer, L. Xu, M. Camara, C. Fazenbaker, R. Fleming, S. Swamynathan, D. Meyer, P.D. Senter, C. Gao, H. Wu, M. Kinch, S. Coats, P.A. Kiener, and D.A. Tice A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo Cancer Res. 68 2008 9367 9374
22. J.W. Lee, H.D. Han, M.M. Shahzad, S.W. Kim, L.S. Mangala, A.M. Nick, C. Lu, R.R. Langley, R. Schmandt, H.S. Kim, S. Mao, J. Gooya, C. Fazenbaker, D. Jackson, D.A. Tice, C.N. Landen, R.L. Coleman, and A.K. Sood EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma J. Natl. Cancer Inst. 101 2009 1193 1205
23. J.W. Lee, R.L. Stone, S.J. Lee, E.J. Nam, J.W. Roh, A.M. Nick, H.D. Han, M.M. Shahzad, H.S. Kim, L.S. Mangala, N.B. Jennings, S. Mao, J. Gooya, D. Jackson, R.L. Coleman, and A.K. Sood EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma Clin. Cancer Res. 16 2010 2562 2570
24. C.M. Annunziata, E.C. Kohn, P. LoRusso, N.D. Houston, R.L. Coleman, M. Buzoianu, G. Robbie, and R. Lechleider Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors Invest. New Drugs 31 2013 77 84
25. S. Imai, K. Nagano, Y. Yoshida, T. Okamura, T. Yamashita, Y. Abe, T. Yoshikawa, Y. Yoshioka, H. Kamada, Y. Mukai, S. Nakagawa, Y. Tsutsumi, and S. Tsunoda Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins Biomaterials 32 2011 162 169
26. H.C. Aasheim, S. Patzke, H.S. Hjorthaug, and E.F. Finne Characterization of a novel Eph receptor tyrosine kinase, EphA10, expressed in testis Biochim. Biophys. Acta 1723 2005 1 7
27. K.E. Huber, L.A. Carey, and D.E. Wazer Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy Semin. Radiat. Oncol. 19 2009 204 210
28. P.J. Roberts, and C.J. Der Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 26 2007 3291 3310
29. I. Zachary VEGF signalling: integration and multi-tasking in endothelial cell biology Biochem. Soc. Trans. 31 2003 1171 1177
30. H. Zhong, and J.P. Bowen Molecular design and clinical development of VEGFR kinase inhibitors Curr. Top. Med. Chem. 7 2007 1379 1393
31. B. Boilly, A.S. Vercoutter-Edouart, H. Hondermarck, V. Nurcombe, and X. Le Bourhis FGF signals for cell proliferation and migration through different pathways Cytokine Growth Factor Rev. 11 2000 295 302
32. M.B. Buck, and C. Knabbe TGF-beta signaling in breast cancer Ann. N. Y. Acad. Sci. 1089 2006 119 126
33. H.J. Johansson, B.C. Sanchez, F. Mundt, J. Forshed, A. Kovacs, E. Panizza, L. Hultin-Rosenberg, B. Lundgren, U. Martens, G. Mathe, Z. Yakhini, K. Helou, K. Krawiec, L. Kanter, A. Hjerpe, O. Stal, B.K. Linderholm, and J. Lehtio Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer Nat. Commun. 4 2013 2175
34. M. Scaltriti, P.J. Eichhorn, J. Cortes, L. Prudkin, C. Aura, J. Jimenez, S. Chandarlapaty, V. Serra, A. Prat, Y.H. Ibrahim, M. Guzman, M. Gili, O. Rodriguez, S. Rodriguez, J. Perez, S.R. Green, S. Mai, N. Rosen, C. Hudis, and J. Baselga Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 + breast cancer patients Proc. Natl. Acad. Sci. U. S. A. 108 2011 3761 3766
35. S.L. Tilghman, I. Townley, Q. Zhong, P.P. Carriere, J. Zou, S.D. Llopis, L.C. Preyan, C.C. Williams, E. Skripnikova, M.R. Bratton, Q. Zhang, and G. Wang Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness Mol. Cell. Proteomics 12 2013 2440 2455
36. S. Zhang, W.C. Huang, P. Li, H. Guo, S.B. Poh, S.W. Brady, Y. Xiong, L.M. Tseng, S.H. Li, Z. Ding, A.A. Sahin, F.J. Esteva, G.N. Hortobagyi, and D. Yu Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways Nat. Med. 17 2011 461 469
37. J.O. Moore, M.A. Lemmon, and K.M. Ferguson Tie2 receptor dimerization mediated by its extracellular FNIII domains Biophysical Journal 2013 608a
38. M.A. Schumacher, N. Chinnam, T. Ohashi, R.S. Shah, and H. Erickson Structure of irisin reveals a novel intersubunit beta-sheet fibronectin (FNIII) dimer; implications for receptor activation J. Biol. Chem. 288 2013 33738 33744
39. L. Zabeau, D. Defeau, H. Iserentant, J. Vandekerckhove, F. Peelman, and J. Tavernier Leptin receptor activation depends on critical cysteine residues in its fibronectin type III subdomains J. Biol. Chem. 280 2005 22632 22640
40. G.M. Keating Pertuzumab: in the first-line treatment of HER2-positive metastatic breast cancer Drugs 72 2012 353 360
41. S.M. Swain, S.B. Kim, J. Cortes, J. Ro, V. Semiglazov, M. Campone, E. Ciruelos, J.M. Ferrero, A. Schneeweiss, A. Knott, E. Clark, G. Ross, M.C. Benyunes, and J. Baselga Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study Lancet Oncol. 14 2013 461 471
42. A. Freywald, N. Sharfe, and C.M. Roifman The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1 J. Biol. Chem. 277 2002 3823 3828
43. K. Nagano, S. Kanasaki, T. Yamashita, Y. Maeda, M. Inoue, K. Higashisaka, Y. Yoshioka, Y. Abe, Y. Mukai, H. Kamada, Y. Tsutsumi, and S. Tsunoda Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients Cancer Med. 2 2013 972 977